An investor sued Grail Inc. and three executives, alleging they misled shareholders about the likelihood of success for the company’s NHS-Galleri cancer screening trial.
The trial failed to meet its primary endpoint and caused Grail’s stock to drop over 50%, according to the proposed class action filed Friday in the US District Court for the Northern District of California.
The complaint centers on Grail’s NHS-Galleri trial, designed to show whether the company’s multicancer blood test could reduce late-stage cancer diagnoses.
Throughout 2025, company executives repeatedly expressed confidence in the trial’s prospects, highlighting positive early results and claiming the three-year study ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.